

Investigation of the Possible Role of the Hippo/YAP1 Pathway in Asthma and Allergy

Lili E. Fodor,¹ András Gézsi,¹ Ildikó Ungvári,¹ Ágnes F. Semsei,¹ Zsófia Gál,¹ Adrienne Nagy,² Gabriella Gálffy,³ Lilla Tamási,³ András Kiss,² Péter Antal,⁴ Csaba Szalai^{1,2*}

¹Department of Genetics, Cell- and Immunobiology, Semmelweis University, Budapest, Hungary

²Heim, Pal Children Hospital, Budapest, Hungary

³Department of Pulmonology, Semmelweis University, Budapest, Hungary

⁴Department of Measurement and Information Systems, University of Technology and Economics, Budapest, Hungary

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Purpose: Several lines of evidence indicate that the Hippo/Yes-associated protein 1 (YAP1) pathways might play a role in the pathogenesis of asthma. To investigate the possible role of the Hippo/YAP1 pathway in the pathogenesis of asthma or its phenotypes. **Methods:** The levels of gene expressions of the members of the Hippo/YAP1 were compared. The presence of the proteins of the YAP1 and FRMD6 were analyzed with Western blot in induced sputum of 18 asthmatic subjects and 10 control subjects. Fourteen single nucleotide polymorphisms (SNPs) in the YAP1 gene were genotyped in 522 asthmatic subjects and 711 healthy controls. The results were evaluated with traditional frequentist methods and with Bayesian network-based Bayesian multilevel analysis of relevance (BN-BMLA). **Results:** The mRNA of all the members of the Hippo/YAP1 pathway could be detected in the induced sputum of both controls and cases. A correlation was found between YAP1 mRNA levels and sputum bronchial epithelial cells ($r=0.575$, $P=0.003$). The signal for the FRMD6 protein could be detected in all sputum samples while the YAP1 protein could not be detected in the sputum samples, of the healthy controls and severe asthmatics, but it was detectable in mild asthmatics. The rs2846836 SNP of the YAP1 gene was significantly associated with exercise-induced asthma (odds ratio [OR]=2.1 [1.3-3.4]; $P=0.004$). The distribution of genotypes of rs11225138 and certain haplotypes of the YAP1 gene showed significant differences between different asthma severity statuses. With BN-BMLA, 2 SNPs, genetic variations in the FRMD6 gene proved to be the most relevant to exercise-induced asthma and allergic rhinitis. These 2 SNPs through allergic rhinitis and exercise-induced asthma were in epistatic interaction with each other. **Conclusions:** Our results provided additional evidence that the FRMD6/Hippo/YAP1 pathway plays a role in the pathogenesis of asthma. If additional studies can confirm these findings, this pathway can be a potential novel therapeutic target in asthma and other inflammatory airway diseases.

Key Words: Asthma; genetics; rhinitis; YAP1

INTRODUCTION

Asthma is a chronic respiratory disease mediated by a wide range of environmental and genetic factors.¹ It is characterized by coughing, wheezing, bronchoconstriction, airway hyperresponsiveness, or airway remodelling. Due to its multifactorial nature, several studies have attempted to elucidate the genetic background of asthma pathogenesis.²⁻⁶

The Hippo pathway is highly conserved from *Drosophila melanogaster* to mammals and regulates organ size through promoting apoptosis and inhibiting cell proliferation in the embryonic stages of development.⁷ It is still not exactly known how the pathway is regulated by organ size; however, it has been proposed that FRMD6 (also known as Willin) influences the ac-

tivity of the Hippo pathway by turning on the central kinase cascade.⁸ The members of this signaling cascade, MST1/2 and LATS1/2 with scaffold proteins SAV1 and MOB1, respectively, phosphorylate one another to inhibit YAP1/TAZ, the main effectors of the pathway.⁹ YAP1 and TAZ are transcriptional co-activators that bind to transcription factors, when active, such

Correspondence to: Csaba Szalai, PhD, DSc, Department of Genetics, Cell- and Immunobiology, Semmelweis University, H-1089 Nagyvárad Sq. 4, Budapest, Hungary.

Tel: +36-1-210-2930/56236; Fax: +36-1-303-6968; E-mail: szalaics@gmail.com

Received: August 9, 2016; Revised: November 9, 2016;

Accepted: November 16, 2016

• There are no financial or other issues that might lead to conflict of interest.

as TEAD, SMAD, or TP73, to regulate the expression of anti-apoptotic (e.g., *BIRC5*), or apoptotic genes.¹⁰⁻¹² Recently, it has been shown that *YAP1* is also widely expressed in respiratory epithelial cells of the embryonic and mature lung and that Hippo/YAP1 signalling regulates epithelial cell proliferation and differentiation, and play an important role in embryonic lung maturation and postnatal airway homeostasis.¹³ Furthermore, in mice it has been demonstrated that *YAP* is dynamically regulated during regeneration of the airway epithelium following lung injury, suggesting a possible role of Hippo/YAP1 signaling in the pathogenesis of acute and chronic lung diseases.¹⁴

Previously, it has been found that genetic variations in *FRMD6*, an upstream activator of the Hippo pathway, were associated with asthma.¹⁵ Furthermore, genetic variations in the *BIRC5* gene (also known as survivin), which is one of the target genes of YAP1 (Fig. 1), influenced the susceptibility to the disease.¹⁶ In addition, the sputum mRNA level of *FRMD6* was significantly lower, while that of *BIRC5* was higher in asthmatic patients than in healthy controls.^{15,16}

Based on these data, we hypothesized that the Hippo/YAP1 pathway may play a role in the pathogenesis of asthma. The main aim of our study was to investigate the members of the Hippo pathway and compare their gene expressions in the induced sputum of asthmatic patients and healthy controls. Moreover, we also determined whether genetic variations in the *YAP1* gene can influence the susceptibility of asthma or subgroups of asthma.

To evaluate the role of the Hippo/YAP1 pathway and one of its target genes, *BIRC5*, as a system in asthma and allergy, we also

analyzed our data with the BN-BMLA method, in order to provide more information on the relationship between genetic variations in the *YAP1*, *FRMD6*, and *BIRC5* genes, asthma susceptibility, as well as other types of variables, e.g., allergy, eosinophils, immunoglobulin E (IgE), and asthma phenotypes.

MATERIALS AND METHODS

Subjects

Gene expression analysis was carried out using the induced sputum of 18 asthmatic patients and 10 healthy controls. All the study participants completed a detailed, pre-edited questionnaire. The recent Global Initiative for Asthma (GINA) guidelines (www.ginasthma.org) were used to diagnose asthma by a respiratory medicine specialist. The evaluation of asthma severity was done at the time of acquisition of induced sputum samples from the patients based on patient history, including number of exacerbations per year, lung function test results, medical treatment applied, and response to medication. The asthmatic patients were divided into 4 severity groups; however, Global Initiative for Asthma 1, 2 (mild) and GINA 3, 4 (moderate-severe) were aggregated because of the small number of patients. Of the 18 asthmatic patients, 14 regularly used inhaled corticosteroids (ICS): <500 µg/day beclomethasone dipropionate (BDP) or equivalent (n=5), 500-1,000 µg/day BDP or equivalent (n=7), and >1,000 µg/day BDP or equivalent (n=2); while 4 were considered steroid naive. Controls were healthy volunteers with no previous history of asthma or any airway conditions. All subjects participated in a lung function test




Fig. 1. Examples of signals and pathways regulating *YAP1* activity.²⁵⁻²⁸

(PDD-301/S; Piston Inc., Budapest, Hungary) and were assessed for fractional exhaled nitric oxide (FENO) levels (NIOX MINO; Aerocrine, Solna, Sweden). All the healthy patients had a normal lung function and had no respiratory tract infection 4 weeks prior to the analysis. A skin prick test was also performed for common allergens in order to test the presence of atopy, which is a genetic predisposition to develop allergic rhinitis, atopic dermatitis, and/or asthma. The participants' sex, age, smoking habits, and allergic statuses were compared between cases and controls, and between severity groups, but no statistical significance was found.¹⁶ Table 1 shows a summary of this study population.

The genotyping analysis included 1,233 unrelated individuals, out of which 522 were asthmatic children (mean age \pm standard deviation [SD], 10.20 ± 5.31 years; 218 males and 194 females), and 711 healthy controls (mean age \pm SD, 14.00 ± 11.22 ; 429 males and 282 females). The patients were all Hungarian (Caucasian), from which about 5%, based on state population data, were of Gypsy origin. Asthma was diagnosed based on the GINA guidelines as previously described. Atopy was identified by a positive skin prick test and/or positive total or specific serum IgE levels. The total and specific serum IgE levels were tested with the 3gAllergy blood tests in the Immulite 2000 Immunoassay system (Siemens Healthcare Diagnostics, Tarrytown, NY, USA). The resulting serum IgE levels were either normal or high based on age-specific ranges (kU/L).

Different types of asthma were defined in patients, except for 131 subjects (25%), where not enough information was available on asthma phenotypes; hence altogether, 391 asthmatic children were involved in the phenotype analysis. Asthma was divided into allergic and non-allergic asthma subtypes. If asthma was not provoked by allergens but allergy was also present, the

allergy types were marked. In allergic patients, depending on the types and quantities of allergens, subgroups of indoor, outdoor, or inhalative allergic phenotypes have been created. If asthma exacerbation was provoked by exercise in the medical history of the patients, asthma was categorized as exercise-induced one. If the onset of asthma or asthma exacerbations have been associated with an infection-related acute respiratory illness, asthma was classified as viral-induced one. Non-atopic patients with viral-induced asthma phenotype composed the non-allergic asthma subgroup.¹⁷ Indoor allergens included dust mites, mold, pet dander, and cockroaches, whereas outdoor allergens consisted of different types of pollen. Eosinophil cell counts from blood were measured with the Coulter AXM analyzer, of which the normal relative range was between 1%-6%, and the normal range of absolute eosinophil count was between 50-200/ μ L. The patients had no change of therapy before the blood samples were taken. Neither did they have exacerbations or respiratory infections for at least 4 weeks prior to the blood test. The detailed characteristics of the asthmatic patients partic-

Table 2. Detailed characteristics of asthmatic patients participating in SNP analysis

Clinical and biological characteristics	Asthmatic patients (n=522)
Age \pm SD (yr)	10.2 \pm 5.3
Sex (Male/female)	328/194
Asthma phenotypes/sensitization status of subjects, yes/no*:	n=486
Exercise-induced	155/233
Viral-induced	181/208
Allergic asthma	56/82
Inhalative allergy	298/99
Outdoor allergy	240/149
Indoor allergy	225/164
Comorbidity rhinitis	217/173
Comorbidity conjunctivitis	120/270
GINA status*:	
No. of patients in GINA 1	97
No. of patients in GINA 2	241
No. of patients in GINA 3	48
No. of patients in GINA 4	96
Absolute eosinophil count \pm SD (No./ μ L)	300 \pm 300
No. of patients with normal or high absolute eosinophil count (normal/high)	107/154
IgE \pm SD (kU/L)	467.5 \pm 1,827.9
No. of patients with normal or high IgE level (normal/high)	88/182

SNP, single nucleotide polymorphism; SD, standard deviation; GINA, Global Initiative for Asthma; IgE, immunoglobulin E.

*Data are available on a limited data set only. Normal absolute eosinophil count is $<200/\mu$ L and high absolute eosinophil count is $\geq 200/\mu$ L. Normal IgE level is <200 kU/L, high IgE level is ≥ 200 kU/L.

Table 1. Detailed characteristics of subjects participating in sputum analysis

Clinical and biological characteristics	Asthmatic patients (n=18)	Control subjects (n=10)
Age \pm SD (yr)	43.7 \pm 16.7	29.3 \pm 4.6
Sex (Male/female)	10/8	5/4
Asthma severity:		
Mild (GINA 1, 2)	11	-
Moderate-to-severe (GINA 3, 4)	7	-
Sputum eosinophil (%)	13.1 \pm 12.4	0 \pm 0
Sputum neutrophil (%)	20.3 \pm 17.9	18.1 \pm 9.3
Sputum macrophage (%)	59.8 \pm 21.0	74.8 \pm 8.2
Sputum bronchial epithelial cell (%)	1.2 \pm 1.6	7.1 \pm 5.7
ICS dose \pm SD (μ g)	594.4 \pm 527.4	-
FENO level \pm SD (ppb)	22.6 \pm 12.5	NA
FEV1 level \pm SD (L)	2.3 \pm 0.7	-

SD, standard deviation; GINA, Global Initiative for Asthma; ICS, inhaled corticosteroid; FENO, fractional exhaled nitric oxide; FEV1, forced expiratory volume in 1 second; NA, not available.

ipating in the gene association study are presented in Table 2.

The control children were from the Orthopaedic Department in Budai Children's Hospital or from the Urological Department from Heim Pál Hospital, both in Budapest. The controls had no symptoms of asthma or any airway conditions, nor any need for medication.

Written informed consents were signed by all patients or by their parent/guardian. The study was done according to the Declaration of Helsinki and approved by the Ethics Committee of the Hungarian Medical Research Council.

Sputum induction

Induced sputum was used for gene expression assays and Western blot analysis. Sputum samples were taken and prepared as previously described by Ungvári *et al.*¹⁶

RNA isolation and cDNA production

RNA was isolated successfully from the induced sputum samples of 18 patients and 10 control subjects with the Qiagen Mini RNeasy Kit according to the manufacturer's instructions (Qiagen, Germantown, MD, USA). The cDNA used in the gene expression analysis was produced with the High Capacity cDNA Reverse Transcription Kit from Thermo Fisher Scientific (Thermo Fisher Scientific, Waltham, MA, USA).

Gene expression analysis

Real-time quantitative polymerase chain reaction (PCR) was performed on *LATS1*, *LATS2*, *MST1*, *MST2*, *SAVI*, *YAP1*, *TAZ*, and β -actin genes using the 7900HT Fast Real-Time PCR System (Thermo Fisher Scientific) in which β -actin was used as an endogenous control, and all results were normalized to it.

DNA isolation and genotyping

Genomic DNA was isolated from the whole blood samples of 1,233 individuals using the QIAamp blood DNA midi kit (Qiagen) or the iPrep PureLink gDNA Blood kit on the iPrep Purification Instrument (Invitrogen, Carlsbad, CA, USA). KBiosciences Competitive Allele-Specific PCR (KASP) version 4.0 genotyping assays were used (LGC Genomics, Berlin, Germany) to genotype 14 single nucleotide polymorphisms (SNPs) on the *YAP1* gene (Table 3) according to the manufacturer's instructions. PCR reactions were carried out using the 7900HT Fast Real-Time PCR System (Thermo Fisher Scientific).

Western blot analysis

Western blot analysis was carried out with human induced sputum samples. After sample preparation, cells were lysed in RIPA lysis and extraction buffer (Thermo Fisher Scientific) supplied with Halt protease inhibitor (Thermo Fisher Scientific) at 1x final concentration and centrifuged at $14,000 \times g$ at 4°C for 15 minutes. Total protein content was determined by the Pierce BCA protein assay kit (Thermo Fisher Scientific) according to the manufacturer's instructions. Samples were loaded on 4%-20% Tris-glycine precast gels (Thermo Fisher Scientific) and then blotted onto the Immobilon-PVDF membrane (Bio-Rad Laboratories, Hercules, CA, USA). After blocking, the following antibodies were used. The primary antibodies were anti-FRMD6, anti-YAP1, and anti-GAPDH (Abcam, Cambridge, UK). The secondary antibodies were polyclonal donkey anti-rabbit IgG HRP (Abcam) and polyclonal goat anti-mouse immunoglobulins HRP (Dako, Glostrup, Denmark). The membrane was treated with Pierce ECL plus substrate (Thermo Fisher Scientific) according to the manufacturer's instructions, and bands were

Table 3. Description of selected SNPs and results of the genotyping

SNP	Position according to the NCBI Genome Build 38	Function	Alleles on the forward strand	MAF in cases	MAF in controls	HWE in controls (<i>P</i> value)
rs1820453	chr11:102109604	Promoter	A/C	0.45	0.47	1.00
rs7106388	chr11:102110546	5'UTR	C/T	0.45	0.48	0.82
rs10895257	chr11:102115913	Intron	A/G	0.22	0.24	0.75
rs1426398	chr11:102117330	Intron	C/T	0.45	0.46	1.00
rs11225138	chr11:102123167	Intron	C/G	0.10	0.09	0.15
rs1426394	chr11:102149503	Intron	A/G	0.29	0.31	0.05
rs948737	chr11:102158098	Intron	C/T	0.33	0.36	0.08
rs1942683	chr11:102173916	Intron	A/G	0.40	0.42	0.69
rs11225161	chr11:102199763	Intron	C/T	0.12	0.11	0.35
rs1894116	chr11:102199908	Intron	C/T	0.12	0.12	1.00
rs11225166	chr11:102219736	Intron	C/G	0.11	0.12	0.71
rs8504	chr11:102232869	3'UTR	A/G	0.42	0.44	0.49
rs2846836	chr11:102234942	Downstream	C/T	0.44	0.46	1.00
rs7115540	chr11:102267059	Downstream	A/G	0.36	0.35	0.32

SNP, single nucleotide polymorphism; NCBI, National Center for Biotechnology Information; MAF, minor allele frequency; HWE, Hardy-Weinberg equilibrium.

visualized on a standard X-ray film (Kodak, Rochester, NY, USA).

Frequentist statistical analysis

For sputum analysis, normalized gene-expression levels were compared by the Mann-Whitney *U* or Kruskal-Wallis test as appropriate. Contingency tables were analyzed by Fisher's exact test. Correlation studies were performed by the Spearman non-parametric test. Differences were considered significant if $P < 0.05$. Allele frequencies between the groups of case and control subjects were estimated by allele counting and tested for deviation from Hardy-Weinberg equilibrium (HWE) by the software program DeFinetti (<https://ihg.gsf.de/cgi-bin/hw/hwa1.pl>). For the significant deviation threshold, we used a P value of < 0.05 .

SNP data were analyzed using SPSS software version 22 (SPSS Inc., Chicago, IL, USA). Logistic regression analyses adjusted for age and gender were used to evaluate the association between *YAP1* genotypes and asthma, its intermediate phenotypes, the discretized (normal/high) serum IgE and discretized (normal/high) eosinophil levels (see at Subjects) or different phenotypes. Additionally, multinomial logistic regression adjusted for age and gender was used for the analysis of *YAP1* SNPs and GINA statuses. Confidence intervals (CIs) were calculated at the 95% level. Multiple comparisons were corrected for using the Benjamini-Hochberg correction, and a new significance level of $P = 0.004$ with the false discovery rate (FDR) $< 6.5\%$ was estimated. Haplotype analysis was carried out with the Haploview 4.2 program (Broad Institute of MIT, Cambridge, MA, USA). Odds ratios (ORs) for haplotypes were counted by VassarStats software (<http://vassarstats.net/index.html>).

Bayesian statistical analysis

Earlier, we have developed an alternative, a systems biological statistical method, named Bayesian network based Bayesian multilevel analysis of relevance (BN-BMLA). Bayesian networks offer a rich language for genetic association studies, because they exhaustively and exactly represent strongly relevant variables and their interactions through the Markov Blanket Set and Markov Blanket Graph features and they are able to evaluate multiple targets. Furthermore, this Bayesian global relevance analysis method provides posterior probabilities, which are direct statements about hypotheses; thus, it can also be used to construct probabilistic data analytic knowledge bases in genetic association studies to support complex querying, off-line meta-analysis, and fusion with background knowledge.¹⁸⁻²¹

We have previously described the BN-BMLA method in detail,^{15,22-24} so that the following only briefly summarizes this approach.

A Bayesian network is a directed acyclic graph (DAG) that aids the discovery of various dependency relations between random variables by representing their joint probability distribution. A node in the network represents a variable, and edges

connecting 2 nodes represent direct dependency between those variables. To find the dependence relations of the variables, a DAG that best describes the dataset must be found. In most cases, there are many DAGs with non-negligible posteriors, but certain structural features may be extracted accurately. Such a feature is based on the concept of strong relevance of a single variable or a set of variables. Bayesian learning allows the evaluation of the strength of the data indicating the presence of a certain feature by evaluating its *a posteriori* probability.

The *a posteriori* probability can be calculated for strongly relevant variable sets with regard to a target variable. The strongly relevant variables have direct impacts on the target. The *a posteriori* probability of the strong relevance is between 0 and 1, where 1 means that the target (e.g., phenotypes of asthma) most certainly has a dependency relationship with a predictor (e.g., SNP), on the other hand 0 means that there is no such relationship. Posterior probabilities of strong relevance greater than or equal to 0.5 are regarded as relevant, and above 0.75 as convincing.¹⁸⁻²¹

In the present study, 29 SNP in the *YAP1*, *FRMD6*, and *BIRC5* genes (genotyped with the same methods and on the same populations;^{15,16} Supplementary Table S1) and the characteristics of the patients detailed in Table 2 were involved in the BN-BMLA analysis.

RESULTS

Gene expression in induced sputum

In the induced sputum of 18 asthmatic patients and 10 control subjects, we measured the gene expression level of 7 members of the Hippo/YAP1 pathway. The expression of all genes was detected in both cases and controls. The mean gene expression level of *YAP1* was slightly lower in the asthmatic patients than in the control subjects ($P = 0.032$, Fig. 2A). No other differences were detected in this respect. We investigated whether within the asthma group there were differences in gene expression between the subgroups of patients defined by GINA status, but no significant differences were found.

During the correlation studies, we found a significant and positive correlation between *YAP1* mRNA levels and sputum bronchial epithelial cells ($r = 0.575$, $P = 0.003$; Fig. 2B). There was a significant and negative correlation between *TAZ* mRNA and sputum neutrophils ($r = -0.509$, $P = 0.009$), and *STK4* showed a significant and positive correlation with sputum eosinophils ($r = 0.425$, $P = 0.034$). There was no significant correlation of *YAP1*, *TAZ*, *LATS1*, *LATS2*, *SAV1*, *STK3*, or *STK4* gene expression with other cellular components, asthma severity, age, gender, airway inflammation, or ICS dose.

SNP association study results

We examined whether any of the SNPs in the *YAP1* gene influence the susceptibility of asthma or different phenotypes.




Fig. 2. (A) *YAP1* mRNA levels in the induced sputum of asthmatic patients ($n=18$) and controls ($n=10$). (B) Relationship between *YAP1* mRNA and bronchial epithelial cell levels. The mRNA levels were normalized and expressed according to the delta delta Ct method. The Mann-Whitney U test (A) and Spearman's non-parametric correlation (B) were used.

Table 4. Significant results of the association analysis of *YAP1* SNPs with asthma phenotypes

Phenotype	SNP	Model	Alleles (1/2)	Phenotype	Genotypes			No.	Pvalue	OR (95% CI)
					11 (%)	12 (%)	22 (%)			
Exercise-induced asthma	rs2846836	Additive	C/T	Present	37 (27)	77 (57)	22 (16)	136	0.004	2.1 (1.3–3.4)
				Absent	80 (38)	80 (38)	51 (24)	211		
GINA 1, 2 vs. 3, 4	rs11225138	Dominant	G/C	GINA 1, 2	261 (83)	53 (17)	-	314	0.003	2.8 (1.4–5.6)
				GINA 3, 4	87 (70)	37 (30)	-	124		

In case of rs2846836 genotypes 11, 12, and 22 are TT, CT, and CC, respectively. In case of rs11225138 genotypes 11, 12, and 22 are GG, GC, and CC, respectively. SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval; GINA, Global Initiative for Asthma.

The statistically significant genotyping results are summarized in Table 4. There was no significant association of the SNPs with asthma susceptibility, allergic status, inhalative, outdoor, indoor allergies, allergic and non-allergic asthma, comorbidities of rhinitis and conjunctivitis or serum IgE and eosinophil levels. However, SNP rs2846836 was significantly associated with exercise-induced asthma (OR=2.1 [1.3–3.4], $P=0.004$, power=0.83; Table 4 and Supplementary Fig. S1A). Additionally, the distribution of genotypes of SNP rs11225138 showed a significant difference between GINA 1–2 and GINA 3–4 statuses in a dominant model (OR=2.8 [1.4–5.6], $P=0.003$, power=0.83; Table 4 and Supplementary Fig. S1B).

In order to find more evidence for the associations, we also conducted haplotype analyses. We found a significant difference between patients of GINA 2 and GINA 3 when we compared the frequencies of a haplotype formed by the rare alleles of SNPs rs1426398 and rs11225138, where the frequency of TC haplotype was more prevalent in GINA 3 than in GINA 2 (28% vs 8%, $P=10^{-7}$). Furthermore, the CA haplotype from SNPs rs11225138 and rs1426394, also showed a significant difference when patients with GINA 3 were compared to GINA 2 asthmatics (26% vs. 7%, $P=10^{-7}$). When we included more than 2 SNPs in the analysis, additional associations were found. Corresponding results are shown in Supplementary Table S2 and

Supplementary Fig. S2.

Western blot analysis of induced sputum

Western blots were carried out on the proteins of the Hippo/*YAP1* pathway whose genetic variations showed significant associations with asthma or phenotypes. Earlier, we found a strong significant association between a genetic variation in the *FRMD6* gene and asthma ($P<0.001$, Supplementary Table S1),¹⁵ and in the present study genetic variations and haplotypes in the *YAP1* gene was associated with different phenotypes of asthma.

The signal for the *FRMD6* protein could be detected in all sputum samples from both asthmatic patients and control subjects. Interestingly, although the *YAP1* protein was not detected in the sputum samples of the healthy controls, it was seen in the sputum samples of the mild asthmatics (GINA 1, 2) and was absent in the sputum of severe (GINA 3, 4) asthmatics (Supplementary Fig. S3).

BN-BMLA

Based on the genotyping results of 29 SNPs in *YAP1*, *FRMD6*, and *BIRC5* genes, the laboratory data and characteristics of the asthmatic patients detailed in Table 2, the posterior probabilities of relevance between the variables with respect to target

variables were calculated by BN-BMLA.

Table 5 shows the most relevant variables with high posterior probabilities according to the BN-BMLA analysis. As expected, e.g., IgE levels or inhalative allergy was highly relevant to allergic asthma or eosinophil levels and allergic conjunctivitis to allergic rhinitis.

In the case of genetic variations, no direct SNP-SNP or gene-gene interactions were found. The most relevant association

Table 5. The most relevant results of the BN-BMLA statistical method

Target variable/Variable	<i>A posteriori</i> probability
Exercise-induced asthma/ Non-allergic asthma	0.90
Allergic conjunctivitis	0.78
Allergic rhinitis	0.99
rs9671722 (<i>FRMD6</i>)	0.99
Allergic asthma/ IgE level	0.75
Inhalative allergy	1.00
Allergic rhinitis/ Inhalative allergy	0.88
Allergic conjunctivitis	1.00
Eosinophil number	1.00

Numbers show the *a posteriori* probability of the strong relevance of a given variable with respect to the target variable.

BN-BMLA, Bayesian network based Bayesian multilevel analysis of relevance; IgE, immunoglobulin E.

was between rs9671722 in the *FRMD6* gene and exercise-induced asthma with *a posteriori* probability of strong relevance of 0.99. Fig. 3 shows the most likely subgraph of the dependence structure of the variables. This structure suggests a direct relevance of rs9671722 to exercise-induced asthma, while another SNP (rs3751464) of the *FRMD6* gene was found to be directly relevant to allergic rhinitis and transitively associated through allergic rhinitis with exercise-induced asthma.

The relationship was confirmed by logistic regression which showed that patients with GG genotypes of the rs9671722 SNP had the highest odds of having both allergic rhinitis and exercise-induced asthma (OR=18.0 [5.9–54.9], $P=3.7E-7$; Supplementary Table S3). The interaction term in the logistic regression model was significant ($P=0.010$).

In Supplementary Fig. S4, another graph is presented which shows a dendrogram of the subsets of strongly relevant variables with respect to allergic rhinitis.

DISCUSSION

Recent studies have shown that inflammation caused by tissue damage or microbial invasion not only plays an important role in host defense, but also triggers regeneration and repair. It was also shown that house dust mite-induced asthma leads to a significant increase in reactive oxygen species (ROS) production and DNA damage in lung tissues, especially in the bronchial epithelium.²⁵ However, the mechanisms, by which inflammation, ROS and DNA damage stimulate regenerative responses




Fig. 3. DAG of the most likely relations of variants and targets. The directed edges represent only probabilistic relationships between the variables which are not necessary causal. DAG, directed acyclic graph.

es remain unclear.

Originally, it was found that the Hippo/YAP1 pathway played an important role in the regulation of organ size, but recent studies have indicated that YAP1 protein could also be detected in peripheral respiratory epithelial cells of the adult mouse lung.¹⁴ Furthermore, it was shown, that after depletion of club cells in the lungs, the distribution and intensity of YAP1 staining were increased. After 10 days, when the regeneration of the bronchiolar epithelium was complete, the YAP1 level and distribution was similar to that in the uninjured airway.¹⁴ In addition, multiple lines of evidence link the Hippo pathway to oxidative stress or ROS-initiated signaling pathways and various pathological processes. YAP1, the major Hippo downstream target, also mediates ROS-triggered signaling.²⁶ These findings in mice suggest that the Hippo/YAP1 pathway can also play an important role in the regeneration processes in human asthma.

Earlier, we carried out a partial genome screening in pediatric asthma and identified the *FRMD6* gene which showed the most consistent association with asthma susceptibility and its role in asthma development was also confirmed in an animal model.¹⁵ In an independent study, we identified *BIRC5*, of which genetic variations influenced asthma susceptibility and expression changed significantly during asthma both in animal and human studies.¹⁶ As *FRMD6* is a possible upstream mediator of the Hippo pathway and *BIRC5* is a target gene of YAP1, these findings also indicated that the Hippo/YAP1 pathway might play a role in asthma.

In the present and earlier studies, we found that all the important members of the *FRMD6*/Hippo/YAP1 pathway were expressed in the human induced sputum in both asthmatic patients and healthy controls. The gene expression level of different components of the Hippo pathway correlated with diverse cell types. This may indicate the main sources of these mRNA in the sputum, suggesting that the regulation of their expressions may be different in these cells and that the genes have additional, diverse functions in these cells.

The gene YAP1 expression level was correlated with the number of sputum bronchial epithelial cells, suggesting its possible origin. The *YAP1* mRNA level was not correlated to the severity of asthma or other asthma phenotypes. On Western blot, however, the protein product for *YAP1* was detected only in mild asthmatics and was not seen in controls or in severe asthmatics.

It has been suggested that YAP1 is regulated by the Hippo pathway which is a kinase cascade that ends up phosphorylating and inhibiting the protein. Recently, several studies have indicated that Hippo-mediated YAP1 phosphorylation is really a fundamental input for YAP1 regulation, but not the only one. Inflammation, DNA damage, and ROS or mechanical signals can represent separate signals with partly independent pathways that can regulate YAP1 phosphorylation and activity.²⁵⁻²⁹

The mechanisms of YAP1 inhibition by phosphorylation are nuclear exclusion, sequestration in the cytoplasm, or protea-

somal degradation. In the present study, *YAP1* mRNA was detected in all samples, but YAP1 protein was detected only in mild asthmatics. Although the detection level of the RT-PCR is lower than that of the Western blot, this finding is in agreement with the previous notion that YAP1 activity is also and perhaps mainly regulated on the protein level. Because of the low number of patients and the detection method, this can only be regarded as a preliminary finding, but based on the above-described observations, the appearance of YAP1 in the mild asthmatics can be explained by the asthma-associated tissue damage that induces regeneration where the Hippo/YAP1 pathway can play an important role.³⁰⁻³² Inflammation, DNA damage, and elevated ROS in the airway epithelium were all found to be associated with an increased YAP1 protein level.²⁶ Presently, it cannot be explained why the YAP1 protein could not be detected in the sputum samples of severe asthmatics. However, it can be hypothesized that by an unknown mechanism, YAP1 is less or not activated in the lung of severe asthmatics which can result in a defected regeneration process in the airways which can contribute to irreversible organ damage and the severity of symptoms in these patients.

Here, we have to mention some limitations of our study. First, although Western blot can determine the molecular weight of protein and in this way has a higher specificity compared to e.g., enzyme-linked immunosorbent assay (ELISA), it is less sensitive to and less capable of quantitative measurement. Secondly, in this study we did not differentiate between dephosphorylated YAP1 and phosphorylated YAP1. Also, as we have no available data on when ICS were administered, we cannot exclude the possibility that various time intervals between ICS administration and sputum induction may influence our results.

The possible role of the Hippo/YAP1 pathway in asthma is further supported by the results that a genetic variation in the *YAP1* gene was found to be associated with exercise-induced asthma and that distributions of certain haplotypes differed significantly between different asthma GINA statuses. This latter observation, in line with the lack of YAP1 protein in the induced sputum of severe asthmatics, also supports the finding that haplotypes in the *YAP1* gene were associated with the severity of the disease. It must be noted, however, that there can be differences between childhood and adult asthma; thus, the genetic associations must be confirmed in a well characterized adult population.

Based on our genotyping results and the characteristics of the asthmatic patients, we searched for the most probable interaction networks with respect to different target variables. We also wanted to know whether there would be interactions between the three genes (*FRMD6*, *YAP1*, and *BIRC5*) whose genetic variations could be associated with asthma or asthma phenotypes in this population. Using the BN-BMLA method, no interaction was found between these genes, indicating that the genetic variations in the 3 genes influenced disease susceptibility inde-

pendently from one another and that the studied population was too small to detect such interactions.

Within the asthma group, 2 genetic variations in the *FRMD6* gene proved to be the most relevant to exercise-induced asthma and allergic rhinitis. The 2 SNPs through allergic rhinitis and exercise-induced asthma were in epistatic interaction with each other. The term exercise-induced asthma describes transient narrowing of the airways after exercise. Presently, the exact mechanism of exercise-induced asthma is not known, but as mouth breathing is common during exercise, there is increased penetration of pollutants, cold air, and allergens into the airways that can lead to epithelial damage, inflammation, and remodeling.^{33,34} Based on the literature and our findings, it is not possible to explain the relationship between the variations in the *FRMD6* gene, rhinitis, and exercise-induced asthma, but a possible hypothesis can be that variations in the gene can weaken the regeneration capacity of the Hippo pathway which can lead to persistent epithelial damage and asthma symptoms in genetically susceptible individuals.

CONCLUSION

This study provides additional evidence that the *FRMD6*/Hippo/YAP1 pathways might play a role in the pathogenesis of asthma and its different subtypes. Naturally, genetic associations must be confirmed in independent populations and it would be also interesting to reveal how exactly the activity of YAP1 protein is regulated in the airways of asthmatic patients. If additional studies can confirm that YAP1-associated pathways play a role in the regeneration processes in airway inflammations, these pathways can be potential novel therapeutic targets in asthma and other inflammatory airway diseases.

ACKNOWLEDGMENTS

This study was supported by Hungarian Scientific Research Fund (OTKA) K81941, K112872 (C. Szalai); and National Research and Technology (NKTH) TECH_08-A1/2-2008-0120 (C. Szalai).

REFERENCES

- Chen Y, Wong GW, Li J. Environmental exposure and genetic predisposition as risk factors for asthma in China. *Allergy Asthma Immunol Res* 2016;8:92-100.
- Yoon HI. Respiratory review of 2014: asthma. *Tuberc Respir Dis (Seoul)* 2014;77:237-42.
- Meyers DA, Bleecker ER, Holloway JW, Holgate ST. Asthma genetics and personalised medicine. *Lancet Respir Med* 2014;2:405-15.
- Vahedi G, Richard AC, O'Shea JJ. Enhancing the understanding of asthma. *Nat Immunol* 2014;15:701-3.
- Tizaoui K, Kaabachi W, Hamzaoui K, Hamzaoui A. Association of single nucleotide polymorphisms in toll-like receptor genes with asthma risk: a systematic review and meta-analysis. *Allergy Asthma Immunol Res* 2015;7:130-40.
- Zhao CN, Fan Y, Huang JJ, Zhang HX, Gao T, Wang C, et al. The association of GSDMB and ORMDL3 gene polymorphisms with asthma: a meta-analysis. *Allergy Asthma Immunol Res* 2015;7:175-85.
- Huang J, Wu S, Barrera J, Matthews K, Pan D. The hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila Homolog of YAP. *Cell* 2005;122:421-34.
- Angus L, Moleirinho S, Herron L, Sinha A, Zhang X, Nestrata M, et al. Willin/*FRMD6* expression activates the hippo signaling pathway kinases in mammals and antagonizes oncogenic YAP. *Oncogene* 2012;31:238-50.
- Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, et al. Inactivation of YAP oncoprotein by the hippo pathway is involved in cell contact inhibition and tissue growth control. *Genes Dev* 2007;21:2747-61.
- Alarcón C, Zaromytidou AI, Xi Q, Gao S, Yu J, Fujisawa S, et al. Nuclear CDKs drive Smad transcriptional activation and turnover in BMP and TGFβ pathways. *Cell* 2009;139:757-69.
- Strano S, Munarriz E, Rossi M, Castagnoli L, Shaul Y, Sacchi A, et al. Physical interaction with Yes-associated protein enhances p73 transcriptional activity. *J Biol Chem* 2001;276:15164-73.
- Vassilev A, Kaneko KJ, Shu H, Zhao Y, DePamphilis ML. TEAD/TEF transcription factors utilize the activation domain of YAP65, a Src/Yes-associated protein localized in the cytoplasm. *Genes Dev* 2001;15:1229-41.
- Mahoney JE, Mori M, Szymaniak AD, Varelas X, Cardoso WV. The hippo pathway effector Yap controls patterning and differentiation of airway epithelial progenitors. *Dev Cell* 2014;30:137-50.
- Lange AW, Sridharan A, Xu Y, Stripp BR, Perl AK, Whitsett JA. Hippo/Yap signaling controls epithelial progenitor cell proliferation and differentiation in the embryonic and adult lung. *J Mol Cell Biol* 2015;7:35-47.
- Ungvári I, Hullám G, Antal P, Kiszel PS, Gézsi A, Hadadi É, et al. Evaluation of a partial genome screening of two asthma susceptibility regions using bayesian network based bayesian multilevel analysis of relevance. *PLoS One* 2012;7:e33573.
- Ungvári I, Hadadi E, Virág V, Bikov A, Nagy A, Semsei ÁF, et al. Implication of BIRC5 in asthma pathogenesis. *Int Immunol* 2012;24:293-301.
- Wenzel SE. Asthma: defining of the persistent adult phenotypes. *Lancet* 2006;368:804-13.
- Antal P, Millinghoffer A, Hullám G, Hajós G, Sárközy P, Gézsi A, et al. Bayesian, systems-based, multilevel analysis of associations for complex phenotypes: from interpretation to decisions. In: Sinoquet C, Mourad R, editors. *Probabilistic graphical models for genetics, genomics, and postgenomics*. Oxford: Oxford University Press; 2014. 318-62.
- Antal P, Millinghoffer A, Hullám G, Hajós G, Szalai C, Falus A. A bioinformatic platform for a bayesian, multiphased, multilevel analysis in immunogenomics. In: Flower DR, Davies M, Ranganathan S, editors. *Bioinformatics for immunomics*. New York (NY): Springer; 2010. 157-85.
- Hullám G, Antal P, Szalai C, Falus A. Evaluation of a Bayesian model-based approach in GA studies. *JMLR Workshop Conf Proc* 2010;8:30-43.
- Antal P, Millinghoffer A, Hullám G, Szalai C, Falus AA. Bayesian view of challenges in feature selection: multilevel analysis, feature

- aggregation, multiple targets, redundancy and interaction. JMLR Workshop Conf Proc 2008;4:74-89.
22. Gézsi A, Lautner-Csorba O, Erdélyi DJ, Hullám G, Antal P, Semsei ÁF, et al. In interaction with gender a common CYP3A4 polymorphism may influence the survival rate of chemotherapy for childhood acute lymphoblastic leukemia. *Pharmacogenomics J* 2015; 15:241-7.
 23. Lautner-Csorba O, Gézsi A, Erdélyi DJ, Hullám G, Antal P, Semsei ÁF, et al. Roles of genetic polymorphisms in the folate pathway in childhood acute lymphoblastic leukemia evaluated by Bayesian relevance and effect size analysis. *PLoS One* 2013;8:e69843.
 24. Lautner-Csorba O, Gézsi A, Semsei ÁF, Antal P, Erdélyi DJ, Schermann G, et al. Candidate gene association study in pediatric acute lymphoblastic leukemia evaluated by Bayesian network based Bayesian multilevel analysis of relevance. *BMC Med Genomics* 2012;5:42.
 25. Chan TK, Loh XY, Peh HY, Tan WN, Tan WS, Li N, et al. House dust mite-induced asthma causes oxidative damage and DNA double-strand breaks in the lungs. *J Allergy Clin Immunol* 2016;138:84-96. e1.
 26. Mao B, Gao Y, Bai Y, Yuan Z. Hippo signaling in stress response and homeostasis maintenance. *Acta Biochim Biophys Sin (Shanghai)* 2015;47:2-9.
 27. Piccolo S, Dupont S, Cordenonsi M. The biology of YAP/TAZ: hippo signaling and beyond. *Physiol Rev* 2014;94:1287-312.
 28. Yin MX, Zhang L. Hippo signaling in epithelial stem cells. *Acta Biochim Biophys Sin (Shanghai)* 2015;47:39-45.
 29. Moleirinho S, Patrick C, Tilston-Lünel AM, Higginson JR, Angus L, Antkowiak M, et al. Willin, an upstream component of the hippo signaling pathway, orchestrates mammalian peripheral nerve fibroblasts. *PLoS One* 2013;8:e60028.
 30. Jeffery PK, Wardlaw AJ, Nelson FC, Collins JV, Kay AB. Bronchial biopsies in asthma. An ultrastructural, quantitative study and correlation with hyperreactivity. *Am Rev Respir Dis* 1989;140:1745-53.
 31. Beasley R, Roche WR, Roberts JA, Holgate ST. Cellular events in the bronchi in mild asthma and after bronchial provocation. *Am Rev Respir Dis* 1989;139:806-17.
 32. Laitinen LA, Heino M, Laitinen A, Kava T, Haahtela T. Damage of the airway epithelium and bronchial reactivity in patients with asthma. *Am Rev Respir Dis* 1985;131:599-606.
 33. Boulet LP, O'Byrne PM. Asthma and exercise-induced bronchoconstriction in athletes. *N Engl J Med* 2015;372:641-8.
 34. Weiler JM, Anderson SD, Randolph C, Bonini S, Craig TJ, Pearlman DS, et al. Pathogenesis, prevalence, diagnosis, and management of exercise-induced bronchoconstriction: a practice parameter. *Ann Allergy Asthma Immunol* 2010;105:S1-47.

Supplementary Table S1. Summary of all SNPs included in the BN-BMLA statistical analysis

Gene	SNP	Position according to the NCBI Genome Build 38	Function	Alleles on the forward strand	MAF in cases	MAF in controls	HWE in controls (p-value)	Significant associations			
								Influenced trait	P value	OR	95% CI
<i>YAP1</i>	rs1820453	chr11:102109604	promoter	A/C	0.455	0.466	0.975				
<i>YAP1</i>	rs7106388	chr11:102110546	5'UTR	C/T	0.455	0.476	0.804				
<i>YAP1</i>	rs10895257	chr11:102115913	intron	A/G	0.222	0.237	0.708				
<i>YAP1</i>	rs1426398	chr11:102117330	intron	C/T	0.448	0.463	0.944				
<i>YAP1</i>	rs11225138	chr11:102123167	intron	C/G	0.103	0.087	0.128	GINA	0.003	2.796	1.403-5.571
<i>YAP1</i>	rs1426394	chr11:102149503	intron	A/G	0.294	0.313	0.055				
<i>YAP1</i>	rs948737	chr11:102158098	intron	C/T	0.326	0.356	0.081				
<i>YAP1</i>	rs1942683	chr11:102173916	intron	A/G	0.395	0.416	0.685				
<i>YAP1</i>	rs11225161	chr11:102199763	intron	C/T	0.117	0.114	0.275				
<i>YAP1</i>	rs1894116	chr11:102199908	intron	C/T	0.120	0.120	0.788				
<i>YAP1</i>	rs11225166	chr11:102219736	intron	C/G	0.110	0.117	0.581				
<i>YAP1</i>	rs8504	chr11:102232869	3'UTR	A/G	0.319	0.338	0.477				
<i>YAP1</i>	rs2846836	chr11:102234942	downstream	C/T	0.439	0.459	0.979	exercise-induced asthma	0.004	2.076	1.256-3.431
<i>YAP1</i>	rs7115540	chr11:102267059	downstream	A/G	0.360	0.354	0.306				
<i>FRMD6</i>	rs3751464	chr14:51651174	promoter	C/T	0.259	0.226	0.270	asthma	0.0003	1.43	1.18–1.75
<i>FRMD6</i>	rs17666653	chr14:51655759	intron	C/T	0.215	0.162	0.397				
<i>FRMD6</i>	rs17666689	chr14:51655901	intron	C/T	0.159	0.141	0.491				
<i>FRMD6</i>	rs9671722	chr14:51660341	intron	G/A	0.185	0.168	0.207				
<i>FRMD6</i>	rs10141001	chr14:51665483	intron	G/A	0.145	0.120	0.800				
<i>FRMD6</i>	rs2277495	chr14:51720248	synonymous codon	C/T	0.305	0.299	0.547				
<i>FRMD6</i>	rs2277494	chr14:51720254	synonymous codon	T/C	0.251	0.258	0.201				
<i>FRMD6</i>	rs7150275	chr14:51728572	3'UTR	A/G	0.251	0.251	0.088				
<i>FRMD6</i>	rs7149810	chr14:51728602	3'UTR	A/G	0.254	0.251	0.095				
<i>BIRC5</i>	rs3764384	chr17:78211647	5'UTR	C/T	0.386	0.464	0.019				
<i>BIRC5</i>	rs3764383	chr17:78212770	3'UTR	A/G	0.280	0.300	0.031				
<i>BIRC5</i>	rs8073903	chr17:78213673	5'UTR	T/C	0.377	0.354	0.078	asthma	0.004	1.458	1.126-1.889
								asthma in females	0.003	1.872	1.232-2.843
								non-allergic asthma in females	0.005	2.808	1.372-5.746
<i>BIRC5</i>	rs17878467	chr17:78214076	5'UTR	C/T	0.114	0.090	0.894				
<i>BIRC5</i>	rs9904341	chr17:78214286	5'UTR	G/C	0.343	0.333	0.549	absolute eosinophil count	0.004	0.917	–0.145 to –0.026
								relative eosinophil level	0.002	0.272	–2.132 to –0.468
<i>BIRC5</i>	rs1508147	chr17:78226507	3'UTR	G/A	0.369	0.482	0.011	non-allergic asthma in females	0.003	3.057	1.445–6.466

Previous results of our research group are also shown.^{15,16}

SNP, single nucleotide polymorphism; BN-BMLA, Bayesian network based Bayesian multilevel analysis of relevance; MAF, minor allele frequency; HWE, Hardy-Weinberg equilibrium.

Supplementary Table S2. YAP1 haplotypes which showed the association with asthma severity

SNPs involved in the haplotype analysis										Haplotype	GINA 2 status in asthma	GINA 3 status in asthma	P value	OR	95%CI
rs1820453	rs7106388	rs10895257	rs1426398	rs11225138	rs1426394	rs948737			ACGTAC	7%	25%	0.00002	4.257	2.393-7.573	
rs1820453	rs7106388	rs10895257	rs1426398	rs11225138	rs1426394	rs948737			ACATGGT	21%	14%	0.121	0.591	0.316-1.103	
rs1820453	rs7106388	rs10895257	rs1426398	rs11225138	rs1426394	rs948737			CTGGCAG	56%	50%	0.313	0.792	0.511-1.228	
rs1820453	rs7106388	rs10895257	rs1426398	rs11225138	rs1426394	rs948737			AGTGGT	5%	7%	0.454	1.501	0.628-3.590	
	rs7106388	rs10895257	rs1426398	rs11225138	rs1426394	rs948737			CGTCAC	7%	25%	0.00002	4.257	2.393-7.573	
	rs7106388	rs10895257	rs1426398	rs11225138	rs1426394	rs948737			CATGGT	21%	14%	0.122	0.606	0.324-1.132	
	rs7106388	rs10895257	rs1426398	rs11225138	rs1426394	rs948737			TGGGAC	56%	50%	0.313	0.792	0.511-1.228	
	rs7106388	rs10895257	rs1426398	rs11225138	rs1426394	rs948737			CGTGGT	6%	7%	0.634	1.325	0.560-3.138	
		rs10895257	rs1426398	rs11225138	rs1426394	rs948737			GTACAC	8%	23%	0.000039	3.576	1.998-6.400	
		rs10895257	rs1426398	rs11225138	rs1426394	rs948737			ATGGT	20%	14%	0.155	0.614	0.328-1.147	
		rs10895257	rs1426398	rs11225138	rs1426394	rs948737			GCGAC	56%	52%	0.500	0.846	0.546-1.313	
		rs10895257	rs1426398	rs11225138	rs1426394	rs948737			GTGGT	6%	6%	0.810	1.124	0.451-2.800	
		rs10895257	rs1426398	rs11225138	rs1426394	rs948737			GTCA	8%	25%	0.000005	4.009	2.265-7.095	
		rs10895257	rs1426398	rs11225138	rs1426394				ATGG	20%	14%	0.155	0.622	0.333-1.162	
		rs10895257	rs1426398	rs11225138	rs1426394				GCGA	57%	55%	0.652	0.890	0.573-1.381	
		rs10895257	rs1426398	rs11225138	rs1426394				GTGG	5%	5%	1.000	0.964	0.361-2.576	
		rs1426398	rs11225138	rs1426394	rs948737				TCAC	8%	23%	0.000039	3.576	1.998-6.400	
		rs1426398	rs11225138	rs1426394	rs948737				TGGT	26%	20%	0.245	0.712	0.414-1.225	
		rs1426398	rs11225138	rs1426394	rs948737				CGAC	56%	52%	0.500	0.846	0.546-1.313	
		rs1426398	rs11225138	rs1426394					TCA	8%	25%	0.000007	3.895	2.206-6.877	
		rs1426398	rs11225138	rs1426394					TGG	26%	18%	0.118	0.621	0.354-1.090	
		rs1426398	rs11225138	rs1426394					CGA	57%	55%	0.653	0.897	0.578-1.393	
		rs1426398	rs11225138	rs1426394					AC	42%	50%	0.142	1.410	0.909-2.188	
		rs1426398	rs11225138	rs1426394					CT	57%	50%	0.216	0.746	0.481-1.158	
		rs1426398	rs11225138	rs1426394					CG	21%	36%	0.001024	2.220	1.386-3.554	
		rs10895257	rs1426398	rs11225138	rs1426394				CA	21%	14%	0.094	0.584	0.313-1.089	
		rs10895257	rs1426398	rs11225138	rs1426394				TG	58%	50%	0.176	0.721	0.465-1.119	
		rs10895257	rs1426398	rs11225138	rs1426394				GT	21%	32%	0.017	1.799	1.112-2.910	
		rs10895257	rs1426398	rs11225138	rs1426394				AT	21%	14%	0.094	0.584	0.313-1.089	
		rs10895257	rs1426398	rs11225138	rs1426394				GC	58%	55%	0.572	0.860	0.554-1.336	
		rs1426398	rs11225138	rs1426394					TC	8%	28%	0.000001	4.324	2.494-7.496	
		rs1426398	rs11225138	rs1426394					TG	34%	18%	0.002349	0.425	0.244-0.742	
		rs1426398	rs11225138	rs1426394					CG	58%	55%	0.572	0.860	0.554-1.336	
		rs1426398	rs11225138	rs1426394					CA	7%	26%	0.000001	4.497	2.540-7.960	
		rs1426398	rs11225138	rs1426394					GA	66%	55%	0.063	0.648	0.415-1.009	
		rs1426398	rs11225138	rs1426394					GG	26%	19%	0.155	0.659	0.380-1.144	
		rs1426398	rs11225138	rs1426394					AC	68%	74%	0.332	1.308	0.798-2.145	
		rs1426398	rs11225138	rs1426394					GT	27%	23%	0.448	0.797	0.475-1.335	
		rs1426398	rs11225138	rs1426394					AT	4%	3%	0.782	0.745	0.217-2.559	


(Continued to the next page)

Supplementary Table S2. Continued


SNPs involved in the haplotype analysis		Haplotype		GINA 2 status in asthma	GINA 3 status in asthma	P value	OR	95%CI
rs948737	rs1942683	CG		14%	23%	0.030	1.842	1,072-3,164
rs948737	rs1942683	TA		7%	3%	0.176	0.412	0,124-1,368
rs948737	rs1942683	CA		55%	51%	0.575	0.861	0,555-1,335
rs948737	rs1942683	TG		24%	23%	0.896	0.938	0,558-1,577
	rs11225161	AC		62%	51%	0.068	0.649	0,418-1,009
	rs11225161	GT		9%	12%	0.349	1.387	0,704-2,734
	rs11225161	GC		29%	33%	0.391	1.246	0,781-1,990
	rs11225161 rs1894116	CT		90%	78%	0.001122	0.377	0,213-0,667
	rs11225161 rs1894116	TC		10%	22%	0.001122	2.654	1,499-4,699
	rs1894116 rs11225166	CC		10%	22%	0.001122	2.654	1,499-4,699
	rs1894116 rs11225166	TG		90%	78%	0.002252	0.404	0,229-0,713
	rs11225166 rs8504	CG		9%	23%	0.000130	3.198	1,802-5,675
	rs11225166 rs8504	GG		58%	48%	0.071	0.658	0,424-1,021
	rs11225166 rs8504	GA		32%	30%	0.632	0.877	0,543-1,417
	rs8504 rs2846836	GT		10%	28%	0.000009	3.538	2,071-6,045
	rs8504 rs2846836	GC		58%	40%	0.001576	0.481	0,307-0,752
	rs8504 rs2846836	AT		32%	32%	1.000	0.997	0,624-1,592
	rs2846836 rs7115540	CA		52%	34%	0.001695	0.482	0,305-0,762
	rs2846836 rs7115540	TA		14%	23%	0.029	1.874	1,090-3,223
	rs2846836 rs7115540	TG		29%	39%	0.068	1.563	0,991-2,466
	rs2846836 rs7115540	CG		6%	4%	0.632	0.705	0,242-2,058

Supplementary Table S3. Verification of Bayesian results by logistic regression regarding exercise-induced asthma and rs9671722 as variables, and allergic rhinitis as a target variable


Exercise-induced asthma	rs9671722	OR (95%CI)	P value
Not present	GG	1	
Present	GG	18.0 (5.9-54.9)	3.7E-07
Not present	GA or AA	1.6 (0.8-3.1)	0.17
Present	GA or AA	3.0 (0.8-11.4)	0.11




Supplementary Fig. S1. (A) Pie chart of SNP rs2846836 in the non-exercise- and exercise-induced asthma groups; $P=0.004$, OR=2.01 (1.26-3.43). (B) Pie chart of SNP rs11225138 in the mild and moderate-to-severe asthma groups: $P=0.003$, OR=2.80 (1.40-5.57). The percentages were calculated from case numbers. SNP, single nucleotide polymorphism; OR, odds ratio.



Supplementary Fig. S2. Diagram showing a significant difference in the haplotype ACGTCAC of SNPs rs1820453, rs7106388, rs10895257, rs1426398, rs11225138, rs1426394, and rs948737 of *YAP1* between the mild (GINA 2) and moderate (GINA 3) asthma severity groups. SNP, single nucleotide polymorphism; GINA, Global Initiative for Asthma.



Supplementary Fig. S3. Western blot analysis of YAP1 and GAPDH proteins. HeLa, HeLa cell extract.



Supplementary Fig. S4. Dendrogram of the subsets of strongly relevant variables with respect to allergic rhinitis. The nodes in the dendrogram represent strongly relevant subsets of all variables, and the arrows denote the broadening of the subsets. The numbers in the nodes show the *a posteriori* probability that all variables in a given subset are strongly relevant.